Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 (‘Iressa’) in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition

✍ Scribed by J. Albanell; F. Rojo; S. Averbuch; A. Feyereislova; R. Herbst; P. LoRusso; D. Rischin; J. Gee; R. Nicholson; J. Baselga

• Book ID: 117658436
• Publisher: Elsevier Science
• Year: 2001
• Tongue: English
• Weight: 177 KB
• Volume: 37
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/s0959-8049(01)81071-6